Myriad
Myriad Genetics to Market Personalis Biomarker Discovery Platform to Pharma Customers
Myriad will market the ImmunoID NeXT immunogenomics discovery platform to pharma customers using its MyRisk Hereditary Cancer Test, BRACAnalysis CDx, and/or MyChoice CDx assays.
Myriad Genetics to Raise $110M in Public Stock Offering
The Salt Lake City-based genetic testing and precision medicine company is offering 6,470,588 shares of its common stock at a public offering price of $17 per share.
Test Volume Growth Drives Q3 Revenue Gains for Myriad Genetics
Myriad's total revenue grew 23 percent year over year, driven by a strong quarter for hereditary cancer and prenatal testing.
People in the News at CareDx, Myriad Genetics, Danaher, 23andMe, Syantra, More
Executive and academic appointments, promotions, and departures in omics and molecular diagnostics for the week of Oct. 30, 2023.
In Brief This Week: Thermo Fisher, Myriad Genetics, T2 Biosystems, DermTech, More
News items for the week of Oct. 30, 2023
Apr 3, 2023